Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 3

Conditions

Papillomavirus Infections 11Neoplasms 10Uterine Cervical Neoplasms 8Breast Neoplasms 8Condylomata Acuminata 5Prostatic Neoplasms 4Melanoma 4Anus Neoplasms 4Vulvar Neoplasms 3Uterine Cervical Dysplasia 3Lung Neoplasms 3Herpes Zoster 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Vaginal Neoplasms 2Sarcoma 2Neuroblastoma 2Neoplasm Metastasis 2Influenza, Human 2HIV Infections 2Glioma 2Colonic Neoplasms 2Breast Neoplasms, Male 2Wilms Tumor 1Whooping Cough 1Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Tetanus 1Squamous Cell Carcinoma of Head and Neck 1Spondylitis, Ankylosing 1

Interventions

Radiotherapy 9Cisplatin 9pembrolizumab 6Methods 6fludarabine 4Papillomavirus Vaccines 4Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4Early Intervention, Educational 4Cyclophosphamide 4durvalumab 3aldesleukin 3Vaccines, Synthetic 3Vaccines 3Radiosurgery 3Radiation 3Platinum 3Palliative Care 3Paclitaxel 3Nivolumab 3Gemcitabine 3Carboplatin 3Brachytherapy 3Bleomycin 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2lenvatinib 2entinostat 2aflibercept 2Trastuzumab 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Vulvar Neoplasms × Vaccines × Clear all
NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 2 Completed
780 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Beijing Health Guard Biotechnology, Inc

Phase 3 Active not recruiting
2,750 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡